- Home
- MOBX vs ANTX Comparison
MOBX vs ANTX Comparison
Compare MOBX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- ANTX
- Stock Information
- Founded
- MOBX 2020
- ANTX 2017
- Country
- MOBX United States
- ANTX United States
- Employees
- MOBX N/A
- ANTX N/A
- Industry
- MOBX
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- ANTX Health Care
- Exchange
- MOBX Nasdaq
- ANTX Nasdaq
- Market Cap
- MOBX 34.2M
- ANTX 33.2M
- IPO Year
- MOBX N/A
- ANTX 2022
- Fundamental
- Price
- MOBX $0.82
- ANTX $1.06
- Analyst Decision
- MOBX
- ANTX Buy
- Analyst Count
- MOBX 0
- ANTX 2
- Target Price
- MOBX N/A
- ANTX $2.00
- AVG Volume (30 Days)
- MOBX 631.7K
- ANTX 76.3K
- Earning Date
- MOBX 08-13-2025
- ANTX 08-12-2025
- Dividend Yield
- MOBX N/A
- ANTX N/A
- EPS Growth
- MOBX N/A
- ANTX N/A
- EPS
- MOBX N/A
- ANTX N/A
- Revenue
- MOBX $10,692,000.00
- ANTX N/A
- Revenue This Year
- MOBX N/A
- ANTX N/A
- Revenue Next Year
- MOBX N/A
- ANTX N/A
- P/E Ratio
- MOBX N/A
- ANTX N/A
- Revenue Growth
- MOBX 450.28
- ANTX N/A
- 52 Week Low
- MOBX $0.55
- ANTX $0.87
- 52 Week High
- MOBX $2.47
- ANTX $2.70
- Technical
- Relative Strength Index (RSI)
- MOBX 43.93
- ANTX 43.83
- Support Level
- MOBX $0.98
- ANTX $1.05
- Resistance Level
- MOBX $1.00
- ANTX $1.09
- Average True Range (ATR)
- MOBX 0.14
- ANTX 0.03
- MACD
- MOBX -0.02
- ANTX -0.00
- Stochastic Oscillator
- MOBX 9.98
- ANTX 9.43
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.